Amgen HQ in Thousand Oaks, CA JHVEPhoto Earlier this month, Wells Fargo cut its rating on Amgen (NASDAQ:AMGN), stating that success of its GLP-1 candidate MariTide was already priced into the shares. However, trading at 16.6x next year's earnings, the stock seems fairly valued despite 27% price appreciation over the past year. Existing product lines provide a strong foundation for the Amgen's valuation, while a successful conclusion to MariTide's crucial phase II study may provide a bullish catalyst later t ...

PeopleImages Since the publication of my last article, "Amgen: You Haven't Seen Anything Yet," Amgen's (NASDAQ:AMGN) share price has risen by more than 20%, thanks in part to increased speculative interest ahead of upcoming clinical results for MariTide in treating patients suffering from obesity, strong sales of its oncology and osteoporosis franchises, as well as medicines acquired in the Horizon Therapeutics deal. What will be presented in this article? I will discuss in detail several topics that ar ...

First and Only Pill for Children and Adolescents Ages 6-17 with Moderate to Severe Plaque PsoriasisTHOUSAND OAKS, Calif., Aug. 20, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced Otezla® (apremilast) is now available in the U.S. for pediatric use. Earlier this year, the U.S. Food and Drug Administration (FDA) approved Otezla for the treatment of moderate to severe plaque psoriasis in children and adolescents ages 6 and older who weigh at least 20 kg (44 lb) and are candidates for phototherapy or sy ...

Amgen has many growth opportunities ahead, and it also pays a fairly high dividend.If you're looking for a top healthcare company to invest in, you may want to consider looking at one that has multiple fast-growing products in its portfolio. By seeking out diversified growth stocks, you can minimize your risk and reduce significant volatility. If a company has a diverse product mix, it has many ways to grow its operations without being too dependent on a single asset.Amgen (AMGN -0.53%) is coming off a stro ...

Urilux/E+ via Getty Images Investment Overview Amgen Inc. (NASDAQ:AMGN), the Thousand Oaks, California based Pharma giant, reported its Q2 2024 earnings this Tuesday, August 6th. The last time I covered Amgen for Seeking Alpha was in May this year, following Q1 earnings. I gave Amgen stock a “buy” rating, when shares traded at $311, and they subsequently reached a high of $335 — up ~8%, before dipping after Q2 results were announced. First, let's consider the headline figures. Revenues grew by an impres ...

Key TakeawaysAmgen shares fell 5% Wednesday after the drug developer lowered its full-year earnings guidance.Second-quarter revenue jumped 20% year-over-year to $8.4 billion, slightly above expectations, driven by Amgen's October acquisition of Horizon Therapeutics.However, earnings dropped from the year-ago period and missed estimates as costs rose. Amgen (AMGN) shares tumbled 5% Wednesday after the drug developer lowered its full-year earnings guidance. The company said it now expects full-year diluted ea ...

On Tuesday, Amgen Inc. AMGN reported mixed second-quarter results.BMO Capital Markets writes, “A commercially in-line quarter for Amgen underscores the importance of upcoming clinical readouts in obesity and inflammatory disease.” The analyst keeps the Outperform rating with a price target of $362.The analyst notes that while the company’s base business underperformed (Enbrel -6% and Repatha -1% compared to consensus), its growth portfolio had some strength. However, they anticipate greater momentum from Ho ...

Shares may have been likely to fall no matter what the company reported.By no means were Amgen's (AMGN -5.54%) second-quarter numbers "bad." Revenue for most of its core drugs was up year over year, and the slight earnings dip is the predictable result of rising expenses. The pharmaceutical company's outlook remains optimistic as well.Yet, S&P Global Market Intelligence data indicates Amgen shares are down 5.9% as of 12:46 p.m. ET today. The prompt for the sell-off is mostly an earnings miss, but the actual ...

Amgen (AMGN) reported second-quarter 2024 adjusted earnings of $4.97 per share, which beat the Zacks Consensus Estimate of $4.93. Earnings declined 1% year over year due to higher operating costs and higher interest expenses.Total revenues of $8.39 billion beat the Zacks Consensus Estimate of $8.31 billion. Total revenues rose 20% year over year.Total product revenues increased 20% from the year-ago quarter to $8.04 billion. Higher volumes were partially offset by lower selling prices of several drugs. Volu ...

Amgen TodayAMGNAmgen$313.39 -15.56 (-4.73%) 52-Week Range$248.38▼$346.85Dividend Yield2.87%P/E Ratio44.77Price Target$312.63Add to WatchlistAmgen NASDAQ: AMGN is a biotechnology firm that has made its way into the weight loss treatment battle. The company’s shares have performed relatively well in 2024, providing a total return of 16%, outpacing its sector and the market. The Health Care Select Sector SPDR Fund NYSEARCA: XLV has returned 9%.Let's start by exploring Amgen's main products and growth opportuni ...